Ismigen, 7 mg 10 pcs

A combined immunostimulant of bacterial origin for sublingual (sublingual) administration.

It is a polyvalent antigenic complex including lysates of bacteria, the most common pathogens of respiratory infections.

The lysates included in Ismigen are obtained by mechanical action.

Ismigen, like other second generation immunostimulants of bacterial origin, has a nonspecific immunostimulatory and specific vaccinating effect.

Ismigen tablets have an effect on various parts of the immune system.

It stimulates both local cellular and humoral immune response and systemic immune response.

It activates phagocytosis, increases the content of lysozyme in saliva, promotes increase of the number of immunocompetent cells.

Enhances functional and metabolic activity of macrophages (including alveolar) and polymorphonuclear leukocytes.

Activates processes of peroxidation and expression of adhesion molecules on macrophage monocytic cells and granulocytes LEA-1, MAC-1, p-150, ICAT-1, which provides cooperation with T-lymphocytes and antigen-presenting cells and promotes destruction of infectious agents.

Stimulates secretion by macrophage monocytic cells of prostaglandin E2, activates natural killer cells; stimulates release of anti-inflammatory cytokines – interleukin (IL)-1, IL-2, IL-6, IL-8,

./p>

interferon gamma, tumor necrosis factor alpha; inhibits the synthesis of IL-4, IL-12; increases the concentration of secretory immunoglobulin (Ig)A in saliva, serum IgA, IgG, IgM; reduces the concentration of serum IgE.

The treatment with Ismigen reduces the frequency, severity and duration of acute respiratory tract infections; there is relief and leveling of symptoms such as fever, cough,

and the treatment with Ismigen decreases the frequency, severity and duration of acute respiratory tract infections./p>

dyspnea, the need for antibacterial and anti-inflammatory therapy is reduced; in patients with chronic respiratory disease, the drug also prevents exacerbations.

Indications

Acute and subacute infections of the upper and lower respiratory tract: bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis, including complications after influenza (treatment in combination therapy).

Recurrent infections of the upper and lower respiratory tract, chronic bronchitis (prevention of exacerbations).

Active ingredient

Composition

How to take, the dosage

Under the tongue; taken on an empty stomach. The tablet should be held under the tongue until completely dissolved. Sublingual tablets should not be crushed, chewed or swallowed.

Acute and subacute infections of the upper and lower respiratory tracts – 1 tablet a day until the disappearance of symptoms (at least 10 days).

Recurrent infections of the upper and lower respiratory tracts, prevention of exacerbations of chronic respiratory diseases – 1 tablet a day for 10 days.

The prophylactic course includes three cycles of 10 days with 20-day intervals between them. The prophylactic course should not be carried out more often than once or twice a year.

If you miss the next dose, do not double it the next time you take it.

Interaction

Ismigen may be used simultaneously with other medicinal products for treatment of acute and chronic respiratory diseases.

The peculiarities of interaction of Ismigen with other medicinal products have not been described so far.

Special Instructions

Children aged 3 to 6 years should be under adult supervision while taking each dose, until the tablet is completely dissolved in the mouth.

Impact on the ability to drive vehicles and other mechanisms requiring high concentration

No effect.

Contraindications

Side effects

The frequency of side effects is classified according to the recommendations of the World Health Organization:

Overdose

There have been no reports of overdose.

Pregnancy use

It is contraindicated in pregnancy and lactation.

Similarities